Skip to main content

Gleolan FDA Approval History

FDA Approved: Yes (First approved June 6, 2017)
Brand name: Gleolan
Generic name: aminolevulinic acid hydrochloride
Dosage form: Oral Solution
Company: NX Development Corp.
Treatment for: Optical Imaging During Glioma Surgery

Gleolan (aminolevulinic acid hydrochloride) is an optical imaging agent indicated for use in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.

Development timeline for Gleolan

Jun  6, 2017Approval FDA Approves Gleolan (aminolevulinic acid hydrochloride) as an Optical Imaging Agent in Patients with Gliomas

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.